China Shineway Pharmaceutical Group Limited

As of December 31, 2025, China Shineway Pharmaceutical Group Limited carries a market capitalization of 6.50B, placing it among publicly traded companies globally. Its enterprise value stands at -1.55B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

China Shineway Pharmaceutical Group Limited's next confirmed earnings release is scheduled for March 30, 2027.

As of December 31, 2025, China Shineway Pharmaceutical Group Limited has 755.40M shares outstanding.

These figures are as of December 31, 2025.

As of December 31, 2025, China Shineway Pharmaceutical Group Limited maintains a current ratio of 3.71, meaning it holds 3.7x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended December 31, 2025.

As of the close on October 22, 2026, China Shineway Pharmaceutical Group Limited's stock has declined approximately 15.36% over the past 52 weeks. The 50-day moving average sits at 7.96, while the 200-day moving average is 8.67.

As of December 31, 2025, China Shineway Pharmaceutical Group Limited holds 8.42B in cash and equivalents against 372.71M in total debt, resulting in a net debt position of -7.64B. Total book value stands at 8.97B, with working capital of 7.56B providing operational flexibility.